BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Lee Pharmaceuticals (LPHM) Announces Year-End Results


10/19/2005 5:09:35 PM

LOS ANGELES, Dec. 24 /PRNewswire-FirstCall/ -- Lee Pharmaceuticals (BULLETIN BOARD: LPHM) reported results for the three months and fiscal year ended September 30, 2003, as compared to same periods ended September 30, 2002.

A comparison of the operating results is as follows: Three Months Ended Fiscal Year Ended September 30 September 30 (000 omitted) (000 omitted) 2003 2002 2003 2002 Gross revenues $ 1,784 $ 2,534 $ 9,730 $10,154 Net revenues $ 1,605 $ 2,324 $ 8,758 $ 9,226 Net (loss) $ (829) $ (746) $(1,104) $ (911) Current assets $ 3,431 $ 4,034 $ 3,431 $ 4,034 Current liabilities $ 6,956 $ 5,917 $ 6,956 $ 5,917 Total assets $ 6,060 $ 6,888 $ 6,060 $ 6,888 Long-term debt $ 3,386 $ 4,284 $ 3,386 $ 4,284 Total stockholders' (deficit) $(4,592) $(3,488) $(4,592) $(3,488) Per share: Basic (loss) per share $ (.20) $ (.18) $ (.27) $ (.22)

In fiscal 2003, net revenues decreased 5% to $8,758,000 from $9,226,000 in fiscal 2002. The decrease in net revenues was primarily attributed to lower sales volume associated with the Lee(R) Lip-Ex(R) lip balm category. In addition, the Company experienced lower volume from controlled substance/prescription drug items, depilatories and various over-the-counter items. The decrease in net revenues was partially offset by higher sales volume generated from the private label segment and newly acquired brands. The Company's sales returns increased approximately $44,000 or 5% when comparing fiscal years 2003 and 2002. The Company continued to experience the discontinuance of a few of the Company's SKUs (stock keeping units) at the retail store level. The continued expansion into the private label business segment has been positive.

The Company reported a net loss of $1,104,000, or 27 cents per share, during fiscal year 2003. This compares to a net loss of $911,000, or 22 cents per share, in fiscal year 2002. Contributing to the loss during fiscal year 2003 was product line impairment adjustment ($254,000), an increase in the allowance for obsolete inventory ($150,000) and higher consulting services

expense due to expanded analytical testing requirements for many of the Company's products ($138,000).

The Company reported an increase of $502,000 in other income when comparing fiscal years 2003 and 2002. The significant increase was attributed to realized gains from the sale of three of the Company's prior product line acquisitions ($319,000). Also, the Company earned approximately $153,000 which was the Company's portion of the net profits from its investment with another drug company and approximately $60,000 from its new distribution agreement with the same company.

Lee Pharmaceuticals is engaged in the purchase, manufacture, and marketing of a range of consumer products, including over-the-counter drug items, health and beauty aids, cosmetics and prescription drug products containing controlled substances, and dental/orthodontic products.

Lee Pharmaceuticals

CONTACT: Michael L. Agresti of Lee Pharmaceuticals, +1-626-442-3141,ext. 3219


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->